Why the study?
Regulatory approval of the first dual-chamber leadless pacemaker system provides an alternative to conventional transvenous devices, but patient preferences for pacemaker features had not been quantified.
What are patient preferences for features of leadless versus conventional transvenous cardiac pacemakers?
What are patient preferences for features of leadless versus conventional transvenous cardiac pacemakers?
Patients value complication and infection risks most highly when choosing a pacemaker, with preferences split evenly between leadless and conventional transvenous devices.
Answers are grounded in this paper and cite their sources.
Patients prioritize low complication risks in pacemaker choice; hypothesis-generating for shared decision-making tools and preference trials.
BACKGROUND: Regulatory approval of the first dual-chamber leadless pacemaker system provides patients an alternative to conventional transvenous pacemakers. The study objective was to quantify the preferences of patients for pacemaker features. METHODS: Patients with a de novo (ie, initial) pacemaker indication were recruited from 7 US sites to complete a Web-based discrete-choice experiment survey between May 11, 2022, and May 24, 2023. Patients chose between pairs of experimentally designed, hypothetical pacemakers that varied according to type (removable leadless, nonremovable leadless, or conventional transvenous); battery life (5, 8, 12, or 15 years); time since regulatory approval (2 or 10 years); discomfort for 6 months (none or discomfort); and complication risk and infection risk (1%, 5%, or 10%/20% for each). Patients' choice data were analyzed using random-parameter logit models and latent-class analysis. Complication risks and infection risks were found to be the most influential. All else equal, patients would accept maximum risks of complications or infections ranging about 5% to 18% to receive their preferred pacemaker type. CONCLUSIONS: Latent-class analysis revealed strong patient preferences for the type of pacemaker, with a nearly equal split between recent leadless pacemaker technology and conventional transvenous pacemakers. These findings can inform shared decision-making between health care providers and patients. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05327101.
No takes yet. Share an insight, caveat, or question.
Reed et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: